epratuzumab

Epratuzumab is a humanized monoclonal antibody that targets CD22, a protein found on the surface of B cells. It was developed for the treatment of autoimmune diseases, particularly systemic lupus erythematosus (SLE). The mechanism of action of epratuzumab involves binding to CD22, which is thought to modulate B cell activity and reduce the production of autoantibodies that contribute to lupus pathology. Clinical trials have investigated epratuzumab's efficacy and safety in patients with moderate to severe SLE. These studies have generally shown a reduction in disease activity and improvements in certain immunological markers. However, the overall clinical benefit has been variable, and it has not yet received broad regulatory approval for widespread use in lupus. Research has also explored its potential in other B cell-related conditions. Epratuzumab is administered intravenously. Common side effects observed in clinical trials have included infusion-related reactions, nausea, and diarrhea. Its development highlights ongoing efforts to target specific immune cells in the treatment of complex autoimmune disorders.